



Original Scientific Article

**IN VIVO MODEL EXPERIMENT USING LAYING HENS TREATED
WITH *ENTEROCOCCUS FAECIUM* EM41 FROM OSTRICH FAECES
AND ITS ENTEROCIN EM41**

Andrea Lauková¹, Anna Kandričáková¹, Jana Ščerbová¹, Renáta Szabóová², Iveta Plachá¹,
Klaudia Čobanová¹, Monika Pogány Simonová¹, Viola Strompfová¹

¹*Institute of Animal Physiology, Slovak Academy of Sciences, Šoltésovej 4-6,
04001 Košice, Slovakia*

²*University of Veterinary Medicine and Pharmacy, Komenského 73, 041 83 Košice, Slovakia*

Received 30 January 2017; Received in revised form 29 June 2017; Accepted 20 July 2017

ABSTRACT

Enterococcus faecium EM41 is an isolate from ostrich faeces. It produces a thermo-stable proteinaceous substance, bacteriocin (enterocin) EM41 with the highest inhibition activity in late logarithmic phase of growth (25 600 AU/ml). This strain and its enterocin have not been previously tested in animals. Lohmann Brown laying hens (aged 45 weeks) were involved in this model/pilot experiment, divided into 3 groups 6 birds in each. *E. faecium* EM41 applied was a variant treated with rifampicin (10⁹ cfu/ml, dose 400 µl/animal/day) to differentiate it from the other enterococci. Partially-purified enterocin EM41 (Ent EM41, dose 40 µl/animal/day) and its producer were applied to water for 21 days. The experiment lasted 35 days. Sampling was performed at days 0 - 1, 21 (3 weeks of additive application), 35 (2 weeks after cessation of additive application) from every bird. *E. faecium* EM41 sufficiently colonized the intestinal tract of laying hens from the initial concentration 10⁹ cfu/g, its count reached 4.30 log cfu/g at day 21. PCR genotypization confirmed the identity of the EM41 strain with the species *Enterococcus faecium*. *E. faecium* EM41 and its enterocin EM41 showed antimicrobial effects demonstrated by reduction of coagulase-positive and coagulase-negative staphylococci, coliforms, *Pseudomonas* spp., *Aeromonas* spp. and *Campylobacter* spp. The hens were *Salmonella* spp. free. After administration of both additives, phagocytic activity was stimulated with a significant increase. The additives did not negatively influence biochemical and haematological parameters or weight gains.

Key words: *Enterococcus faecium*, enterocin, hens, beneficial effect

Enterococcus faecium EM41 is an isolate from ostrich faeces. It has been genotyped by means of PCR and allotted to the species *E. faecium* (1, 2). This strain produces a thermo-stable proteinaceous substance, bacteriocin (Ent) EM41 which reaches the highest inhibition activity in the late logarithmic phase of growth (25 600 AU/ml). In spite of the fact that modern broiler husbandry tends to improve the efficacy of rearing with appropriate genetic

crossbreeding, rearing conditions and nutrition, birds are still threatened by various diseases such as necrotic enteritis caused by *Clostridium perfringens*, or by salmonellosis, campylobacteriosis and/or eimeriosis, which of course leads to financial loss (3). Nowadays, animal nutritionists are looking for new ways to produce healthy food-producing animals. To prevent overgrowth of undesirable microbiota in the gastrointestinal tract of chickens, many poultry producers use probiotics (4, 5), which can beneficially influence gut microbiota and/or modify their immune system (6). Frequently, the probiotic *Bacillus* spp. or lactobacilli are used in broiler chickens (7). However, beneficial influences involving antimicrobial effects and immune system stimulation using probiotic enterococci and their enterocins have also been reported (8, 9, 10, 11, 12). Following up this information, our study was focused on the strain *Enterococcus faecium* EM41

Corresponding author: Dr. Andrea Lauková, PhD

E-mail address: laukova@saske.sk

Present address: Institute of Animal Physiology, Slovak Academy of Sciences, Šoltésovej 4-6, 040 01 Košice, Slovak Republic

Phone: +421557922964

Copyright: © 2017 Lauková A. This is an open-access article published under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited..

Competing Interests: The authors have declared that no competing interests exist.

Available Online First: 5 August 2017

Published on: 15 October 2017

<https://doi.org/10.1515/macvetrev-2017-0024>

and its enterocin (Ent EM41) to test it in a pilot/model experiment using laying hens to assess their effects on microbiota, biochemical and hematological parameters, phagocytic activity and weight gain. This strain and its enterocin have not been previously tested in animals.

MATERIAL AND METHODS

Preparing of Enterococcus faecium EM41 and its enterocin EM41 for application

The *Enterococcus faecium* EM41 applied was a variant treated with rifampicin prepared as previously reported by Lauková et al. (13). EM41 (0.1% inoculum) was cultivated in MRS broth (Merck, Darmstadt, Germany) for 18 h at 37 °C. The broth culture of the EM41 strain was centrifuged at 10 000 g for 30 min. The supernatant was removed and bacterial cells were re-suspended in Ringer solution (pH 7.0, Merck) to the final concentration of 10⁹ cfu/ml; the cell count was checked by spreading appropriate dilutions of *E. faecium* EM41 culture onto M-Enterococcus agar plates (Difco, Maryland, USA) enriched with rifampicin (100 µl/ml, Himedia, India).

Partially-purified enterocin EM41 (Ent EM41) was prepared according to the protocol reported by Mareková et al. (14) as follows: *E. faecium* EM41 (0.1% inoculum) was cultivated in BHI broth (500 ml, Becton and Dickinson, Cockeysville, USA) for 18 h at 37 °C. The broth culture was centrifuged at 10 000 g for 30 min. The supernatant was precipitated with ammonium sulphate (40% saturation, for 3 hours) and stirring at 4 °C. The precipitate was re-suspended in the phosphate buffer (5 ml, pH 6.5) and diluted in the buffer at ratio 1:1. The inhibition activity of Ent EM41 was tested according to De Vuyst et al. (15) on Brain Heart Infusion Agar (BHI Agar, Becton Dickinson) against the principal indicator strain *E. avium* EA5 and expressed in Arbitrary Units per millilitre (AU/ml); this is associated with the highest dilution of enterocin causing growth inhibition of the indicator strain.

Experimental birds, design of model experiment and sampling

Eighteen Lohmann Brown laying hens (aged 45 weeks) were involved in this model/pilot experiment. Regarding the birds' age, the hens had served previously as the control group in an experiment performed by our colleagues. The

laying hens were fed the standard diet for 35 days as follows: 33.5% wheat bran, 31% maize, 24.5% soy grit, 9% limestone and 2% Premix HYD 10 (Agroconsult Company, Slovakia). All care and experimental procedures involving animals were approved by the Ethical Commission of our Institute of Animal Physiology at the Slovak Academy of Science (Košice, Slovakia) and by the Slovak State Veterinary and Food Administration. The birds were placed in pens (1 animal per pen) according to the EU rules (§ 3 NV 23/2009 Z. z.) in the approved experimental stall (SK U 07016) with access to water *ad libitum*. The hens were provided a light regimen of 15 h light and 9 h dark, including the dark period during the night. The temperature was kept at a value required for the age of the birds (24 – 19 °C) and humidity was maintained in the range of 60 – 80%. The temperature and humidity were recorded continuously with a digital thermograph positioned at the same level as the pens. The pens were provided with a withdrawable part for faeces separation. The experiment lasted 35 days. The hens were divided into three groups (control group - CG; experimental group 1 - EG1; experimental group 2 - EG2; 6 hens in each group, n=6). Every day at the same time in the morning, the hens in EG1 were administered the *E. faecium* EM41 strain (dose 400 µl/bird/day, cells concentration 10⁹ cfu/ml) for 21 days (3 weeks). The birds in EG2 received enterocin (Ent) EM41 (40 µl/animal/day, 25 600 AU/ml). Both additives were applied to the drinking water. The diffusion of EM41 strain and Ent EM41 in the water was checked by plating of water sample dilutions onto M-Enterococcus agar (Difco, Maryland, USA) and expressed in cfu/ml. To check the microbial background, faeces were sampled (n=6) from every bird in sterile bags following the method used by Grešáková et al. (16). Sampling of faeces was carried out from each and every bird at the start of the experiment (day 0 – 1), after 3 weeks of both additives application (day 21) and at the end of the experiment (day 35, 2 weeks after EM41 and Ent EM41 cessation).

Each faecal sample was treated using the standard microbial method; one gram of faeces was mixed in Ringer solution (1:9, pH 7.0, Oxoid Ltd., Basingstoke, Hampshire, United Kingdom) using a Stomacher Masticator (Spain). The appropriate dilutions were double plated onto selected media and cultivated at 24/48 h at 37 °C (depending on the bacteria). The following media according to the International Organization for Standardization (ISO) were used: M-Enterococcus agar (ISO 15214, Difco, USA) enriched with rifampicin (100 µg/l, to

differentiate it from the other enterococci) to count *E. faecium* EM41 strain and without rifampicin for the total enterococcal count. Baird-Parker agar (ISO 6888, Becton Dickinson) supplemented with egg yolk tellurite solution (Merck) was used for enumeration of coagulase-positive staphylococci (CoPS); Mannitol salt agar (Difco) was used to count coagulase-negative staphylococci (CoNS). Coliform bacteria were enumerated on MacConkey agar (ISO 7402, Becton Dickinson, USA). *Pseudomonas* agar (Biomark, India) was used for *Pseudomonas* spp. bacteria. *Campylobacter* agar Karmali (Oxoid, Ltd.) was used to isolate *Campylobacter* spp. To check for *Salmonella* spp., faecal samples were inoculated into Rappaport-Vassiliadis broth (Merck, Germany) and cultivated at 37° C for 24 h. Then 100 µl of culture was plated onto Brilliant Green agar (ISO 6579, Difco). Grown colonies were picked up from BGA and genotyped by means of PCR as previously described by Herich et al. (17). To confirm the EM41 strain detected from faeces after application, the PCR method, primers and protocol according to Woodford et al. (18) were used. The bacterial counts were expressed as log cfu per g of faeces (colony-forming units per gram) ± SD.

Biochemical parameters and phagocytic activity testing

Blood sampling was performed at day 0 - 1 (start of the experiment), at day 21 (3 weeks after of *E. faecium* EM41 and Ent EM41 application) and at day 35 (end of experiment, 2 weeks after cessation of *E. faecium* EM41 and Ent EM41). The blood was sampled from the *vena ulnaris* into nonheparinized sterile Eppendorf tubes to test the biochemical parameters: the total proteins (g/l), albumins (g/l), triglycerides (mmol/l), cholesterol (mmol/l), glucose (mmol/l), calcium (mmol/l) and phosphorus (mmol/l) using the Ransel commercial kit (Randox, United Kingdom). Blood serum was obtained by centrifugation at 3 000 x g for 10 and stored frozen in plastic vials until analysis.

Phagocytic activity (PA) was measured in heparinized blood using the direct counting procedure with microspheric hydrophilic particles (MSHP). Ingestion of MSHP by polymorphonuclear cells (PMNs) was determined with a modified test described by Vetvička et al. (19). Phagocytic activity was calculated as the relative number of white cells containing at least three engulfed particles per 100 white cells (neutrophils) and expressed as a percentage (%). Index of PA (IPA) was calculated as

the number of engulfed particles per total number of neutrophils observed. The percentage of phagocytic cells was evaluated using an optical microscope, by counting PMN cells up to 100.

GPx evaluation, blood analysis and weight control

The activity of glutathione-peroxidase (GPx, EC 1.11.1.9, U/g Hb) in blood erythrocytes was determined from heparinized blood using the specific Ransel commercial test (Randox) according to the spectrophotometric assay procedure of Paglia and Valentine (20). Blood was sampled in heparinized Eppendorf tubes for evaluation of haematological parameters using a CELL – DYN 3700 hemanalyser (Abbot Laboratories, USA). Body weight was registered daily.

Statistical analysis

Statistical analyses of the results were performed using Tukey's multiple comparison test with the level of significance set at $p < 0.05 \pm$ standard deviation (SD), or Dunnett's post test. The results were compared with control or sample collection days.

RESULTS

Table 1a shows counts of *Enterococcus faecium* EM41, total enterococci, CoPS and CoNS in the hens' faeces. *Enterococcus faecium* EM41 colonized the intestinal tract of the laying hens, reaching 4.30 (1.47) cfu/g at day 21 (from the initial concentration 9.0 log cfu/g).

At day 35, the count of EM41 strain was 2.10 (1.32) log cfu/g. PCR genotypization confirmed the identity of the EM41 strain with the species *E. faecium*. Significantly higher counts of enterococci were detected in the faeces of EG1 (EM41) at day 21 compared to EG1 at day 35 ($^{ab}p < 0.05$). The counts of enterococci were balanced at day 0 - 1. On the other hand, at day 21 higher counts (although not significant) of enterococci were found in EG1 compared to EG2- 6.20 (0.46) to 4.49 (0.86) log₁₀ cfu/g ± SD (Table 1a). Ent EM41 could probably inhibit enterococci in EG2. Similar situation was assessed at day 35 in EG1 compared to EG2- 4.50 (1.30) to 3.96 (0.72) log₁₀ cfu/g ± SD (Table 1a). At day 21, higher counts of enterococci were found in EG1 compared to C – 6.20 (0.46) to 5.10 (0.60) ± SD; at day 35 slight reduction of enterococci was

Table 1a. Bacterial profile after *Enterococcus faecium* EM41 and Ent EM41 application and their cessation, expressed in colony - forming units per gram (cfu/g \pm SD)

	EF EM41	Enterococci	CoPS	CoNS
Day 0-1				
EG1	nt	5.75 (0.57)	5.31 (0.75) ^a	5.48 (1.00)
EG2	nt	4.30 (0.45)	4.36 (0.76)	4.89 (0.80)
C	nt	4.90 (0.83)	4.20 (0.74)	4.90 (0.97)
Day 21				
EG1	4.30 (1.47)	6.20 (0.46) ^a	5.20 (0.82)	5.50 (0.57)
EG2	nt	4.49 (0.86)	4.80 (0.64)	4.70 (0.57)
C	nt	5.10 (0.60)	4.94 (0.95)	4.54 (0.80)
Day 35				
EG1	2.10 (1.32)	4.50 (1.30) ^b	3.70 (0.72) ^b	4.03 (0.56)
EG2	nt	3.96 (0.72)	3.70 (1.00)	3.70 (1.20)
C	nt	4.10 (0.95)	3.46 (1.49)	3.52 (0.90)

EG1 - *Enterococcus faecium* EM41; EG2 - Enterocin, Ent EM41; C - control hens; nt - not tested; CoPS, coagulase-positive staphylococci, CoNS, coagulase-negative staphylococci; Day 0-1, start of the experiment; Day 21 - 3 weeks application of *E. faecium* EM41 and Ent EM41; Day 35 - 2 weeks cessation of additives; Enterococci, EG1/Day 21:EG1/Day 35, ^{ab}p<0.05; CoPS, EG1/Day 0-1: EG1/Day 35, ^{ab}p<0.01

found in EG2 compared to C- 3.96 (0.72) to 4.10 (0.95) log 10 cfu/g \pm SD (Table 1a). At day 35, the counts of CoPS were significantly reduced in EG1 compared to day 0 - 1 (^{ab}p<0.01). At day 21, CoPS were slightly decreased in faeces of EG2 compared to EG1-4.80 (0.64) to 5.20 (0.82) log 10 cfu/g \pm SD (Table 1a); CoPS were decreased in EG2 at day 21-4.80 (0.64) log 10 cfu/g \pm SD compared to EG1 at day 0 - 1; 5.31 (0.75) log10 cfu/g \pm SD). Reduction of CoNS was also noted at day 21 in EG2 compared to EG1-4.70 (0.57) to 5.50(0.57) log 10 cfu/g \pm SD); they also decreased at day 35 in EG2 compared to EG1-3.70(1.20) to 4.03 (0.56) log10 cfu/g \pm SD.

Table 1b gives the counts of coliforms, *Pseudomonas* spp., *Aeromonas* spp. and *Campylobacter* spp. in the hens' faeces. The hens

were *Salmonella* spp. cells-free. Reduction of *Campylobacter* spp. was found in the faeces of EG1 at day 21 compared to EG1 at day 0-1; 3.90 (0.83) to 4.50 (0.47) log10 cfu/g \pm SD; at day 35 lower counts of *Campylobacter* spp. were noted in EG1 compared to EG1 at day 0-1; 3.75 (0.86) to 4.50 (0.47) log10 cfu/g \pm SD. Reduction in *Campylobacter* cells was also demonstrated in EG2 at day 21 compared to EG1 at day 21-2.75 (1.30) to 3.90 (0.83) log10 cfu/g \pm SD; at day 21 reduction of *Campylobacter* spp. was indicated in EG1 compared to C-3.90 (0.83) to 4.70 (0.34) log10 cfu/g \pm SD and in EG2 compared to C-2.75 (1.30) to 4.70 (0.34) log 10 cfu/g \pm SD. Decrease in coliforms was noted in EG2 at day 35 compared to EG2 at day 21-4.35 (0.80) to 6.30 (0.97) log 10 cfu/g \pm SD (Table 1b). *Pseudomonas*

Table 1b. Bacterial profile after *Enterococcus faecium* EM41 and Ent EM41 application and their cessation, expressed in colony - forming units per gram (cfu/g \pm SD)

	Coliforms	Campyl	Pseud.	Aerom.
Day 0-1				
EG1	5.18 (1.14)	4.50 (0.47)	7.30 (0.34)	5.50 (0.80)
EG2	6.24 (0.90)	3.95 (0.79)	6.90 (0.35)	5.30 (0.94)
C	5.95 (0.90)	4.20 (0.55)	6.90 (0.90)	5.10 (1.67)
Day 21				
EG1	6.00 (1.64)	3.90 (0.83)	7.01 (0.97)	5.01 (1.42)
EG2	6.30 (0.97)	2.75 (1.30)	6.80 (0.97)	4.81 (1.80)
C	5.60 (1.20)	4.70 (0.34)	7.40 (0.23)	4.57 (1.70)
Day 35				
EG1	5.04 (1.20)	3.25 (1.50) ^c	6.00 (0.68)	3.90 (0.71)
EG2	4.35 (0.80)	3.75 (0.86)	5.98 (0.64)	4.00 (1.10)
C	4.59 (1.50)	3.00 (1.00)	6.10 (0.54)	4.10 (1.90)

EG1 - *Enterococcus faecium* EM41; EG2 - Enterocin, Ent EM41; C - control group of hens; nt - not tested; Day 0 - 1, start of the experiment; Day 21 - 3 weeks application of *E. faecium* EM41 and Ent EM41; Day 35 - 2 weeks cessation of additives; Hens were *Salmonella* spp. free. No significant, however mathematical reduction (tendency to decrease) was found regarding *Campylobacter* spp., coliforms, *Pseudomonas* spp. and *Aeromonas* spp.

Table 2a. Biochemical parameters in sera of hens after additives application and their cessation (average \pm SD)

n=6	Ref. value	EG1	EG2	C
TP (g/l)	55 - 75			
Day 0 - 1		59.7 (3.6)	58.3 (4.2)	55.2 (3.0)
Day 21		56.7 (6.2)	55.9 (3.4)	53.7 (2.8)
Day 35		53.2 (3.6)	55.8 (3.7)	52.9 (3.3)
ALB (g/l)	26 - 40			
Day 0 - 1		42.9 (0.8)	43.4 (0.5)	43.1 (1.1)
Day 21		44.1 (0.7)	42.9 (0.5)	43.0 (0.5)
Day 35		42.8 (0.3)	42.8 (1.0)	42.2 (0.5)
TRIG (mmol/l)				
Day 0 - 1		6.5 (0.8)	5.5 (0.1)	5.3 (1.7)
Day 21		8.0 (1.7)	7.2 (1.8)	6.4 (1.4)
Day 35		7.0 (1.2)	6.4 (1.9)	5.6 (1.8)
CHOL (mmo/l)	3 - 6.6			
Day 0 - 1		4.5 (0.8)	4.1 (0.5)	4.8 (1.3)
Day 21		3.9 (0.4)	4.5 (0.7)	3.6 (0.4)
Day 35		3.9 (0.4)	3.9 (0.4)	3.7 (0.7)
GLU (mmol/l)	3.4 - 6.0			
Day 0 - 1		12.3 (2.4)	12.3 (1.2)	11.3 (1.8)
Day 21		13.8 (1.3)	12.5 (1.9)	12.8 (1.4)
Day 35		13.7 (1.4)	11.9 (2.5)	12.2 (2.5)

EG1 - *Enterococcus faecium* EM41; EG2 - Enterocin (Ent)EM41; C - control group of hens; nt-not tested; Day 0 - 1, start of the experiment; Day 21 - 3 weeks application of *E. faecium* EM41 and Ent EM41; Day 35 - 2 weeks cessation of additives; Ref. value - reference value

spp. were decreased in EG2 at day 21 compared to EG1 at day 0-1; 6.80 (0.97) to 7.30 (0.34) log 10 cfu/g \pm SD; at day 35 in EG1 compared to EG1 at day 0-1; 6.00 (0.68) to 7.30 (0.34) log 10 cfu/g \pm SD (Table 1b). The counts of *Aeromonas* spp. were lower in EG2 at 21 compared to EG2 at 0-1; 4.81 (1.80) to 5.30 (0.94); they were also decreased at day 35 in EG1 compared to EG1 at day 21- 3.90 (0.71) to 5.01 (1.42) log 10 cfu/g \pm SD and at day 35 in EG1 compared to C; 3.90 (0.71) to 4.10 (1.90) log 10 cfu/g \pm SD, (Table 1b).

Biochemical parameters specified from the blood serum in the experimental group (proteins, albumin, triglycerides, cholesterol, glucose,

calcium and phosphorus) were not negatively influenced (Table 2a, 2b). However, glucose values for instance were higher than reference values in all groups at day 35, the lowest being found in EG2 hens (Ent EM41). The total proteins, triglycerides, Ca, P were mostly in their physiological ranges. Albumin was slightly higher; however, not only in the experimental but also in the control group.

PA values were significantly increased in EG1 compared to C at day 21 (Table 3, ^{ab}p<0.05). Increased PA was also noted at day 35 in EG1 compared to C (^{ab}p<0.001), as well as in EG2 compared to C (^{bc}p<0.05). When individual samplings were compared, increased PA was

Table 2b. Biochemical parameters in sera of hens after additives application and their cessation (average \pm SD)

n=6	Ref. value	EG1	EG2	C
Ca (mmo/l)	4.75 - 5.5			
Day 0 - 1		3.9 (0.5)	4.1 (0.2)	3.9 (0.7)
Day 21		4.4 (0.1)	4.2 (0.2)	4.1 (0.2)
Day 35		4.2 (0.2)	4.2 (0.2)	4.1 (0.2)
P (mmo/l)	1.6 - 2.01			
Day 0 - 1		1.8 (0.3)	1.7 (0.1)	1.8 (0.3)
Day 21		1.8 (0.2)	1.8 (0.1)	1.8 (0.3)
Day 35		1.9 (0.2)	1.9 (0.2)	1.7 (0.2)

EG1 - *Enterococcus faecium* EM41; EG2 - Enterocin (Ent)EM41; C - control group of hens; nt-not tested; Day 0 - 1, start of the experiment; Day 21 - 3 weeks application of *E. faecium* EM41 and Ent EM41; Day 35 - 2 weeks cessation of additives; Ref. value - reference value

Table 3. Phagocytic activity in % \pm SD

n=6	PA	EG1	EG2	C
Day 0 - 1		37.13 (1.3) ^c	37.25 (1.5)	36.75 (2.8)
Day 21		39.80 (1.2) ^a	38.75 (1.6)	36.63 (2.8) ^b
Day 35		39.88 (1.4) ^a	38.38 (1.7) ^c	36.38 (1.0) ^b
	IPA			
Day 0 - 1		1.4 (0.2) ^b	1.7 (0.2)	1.5 (0.2)
Day 21		1.7 (0.2) ^c	1.6 (0.3)	1.7 (0.2)
Day 35		1.8 (0.2) ^a	1.5 (0.2)	1.7 (0.2)

PA-phagocytic activity; IPA-index of phagocytic activity; EG1 - *Enterococcus faecium* EM41; EG2 - Enterocin Ent EM41; C - control hens; Day 0 - 1, start of the experiment; Day 21, 3 weeks application of additives; Day 35, 2 weeks cessation of additives; PA – EG21/Day:C/Day 21, ^{ab}p<0.05; EG1/Day 35:C/Day 35, ^{ab}p<0.001; EG2/Day35: C/Day 35 ^{bc}p<0.05; EG1/Day21:EG1/Day0 1, ^ap<0.01; EG1/Day 35:EG1/Day 0-1, ^{bc}p<0.001; IPA, EG1/Day 35: EG1/Day0-1, ^{ab}p<0.001; EG1/Day21: EG1/day 0-1, ^{bc}p<0.01

noted in EG1 at day 21 compared to EG1 at day 0 - 1 (^ap<0.01) and at day 35 in EG1 compared to EG1 at day 0 - 1 (^{bc}p<0.001). The stimulation of non-specific immunity by EM41 strain was also manifested through increased IPA in EG1 at day 35 compared to EG1 at day 0 - 1 (^{ab}p<0.001) and in EG1 at day 21 compared to EG1 at 0-1 (^{bc}p<0.01).

GPx values were not significantly influenced; however, lower values of GPx were measured in

EG2 compared to EG1 and compared to C during the whole experiment (Table 4). The blood cell count was checked using the hemoanalyser only at day 21 (3 weeks after administration of additives). Blood cells ranged in reference values (Table 5). The weight of the hens was not influenced by additives; at day 21 only slight increase in weight was found in EG2 compared to EG1 (difference 66.7 g, Table 6).

Table 4. Values of the enzyme glutathione peroxidase (GPx in U/g Hb \pm SD)

n=6	EG1	EG2	C
Day 0 - 1	73.62 (13.67)	70.45 (3.85)	73.10 (11.73)
Day 21	85.96 (5.36)	72.69 (8.46)	81.36 (12.09)
Day 35	83.11 (10.51)	74.06 (12.59)	76.48 (11.19)

EG1 - hens with application of *Enterococcus faecium* EM41; EG2 - hens with application of enterocin Ent EM41; C - control hens; Day 0-1, start of the experiment; Day 21, 3 weeks application of additives

Table 5. Blood analysis and difference in laying hens at day 21

n=6	EG1	EG2	C	RF
Leucocytes (g/l)	93.95	70.50	91.72	4.6-10.2
Neutrophils (%)	51.50	72.43	47.42	37-80
Eosinophils (%)	2.20	2.42	1.89	0-7
Basophils (%)	14.50	3.83	20.53	0-2.5
Lymphocytes (%)	21.65	15.83	17.54	10-50
Monocytes (%)	10.16	5.47	12.61	0-12
Erythrocytes (T/l)	2. 41	2.31	2.50	4.04-6.13
Hemoglobin (g/l)	140.17	132.17	138.33	122-181
Hematokrit l/l	0.30	0.28	0.30	0.37-0.54
Thrombocytes (g/l)	3.75	3.72	2.12	1.42-4.24

EG1 - hens with application of *Enterococcus faecium* EM41; EG2 - hens with application of enterocin Ent EM41; C - control hens; Day 0 - 1, start of the experiment; Day 21, 3 weeks application of additives; RF - reference values

Table 6. Weight of hens in individual sampling (in grams \pm SD)

Means of n=6	EG1	EG2	C
Day 0 - 1	1544.6 (39.30)	1596.7 (39.95)	1611.9 (40.14)
Day 21	1552.3 (39.40)	1619.8 (40.24)	1594.3 (39.92)
Day 35	1563.1 (39.50)	1545.2 (39.30)	1567.0 (39.58)

EG1-hens with application of *Enterococcus faecium* EM41; EG2 - hens with application of enterocin Ent EM41; C - control hens; Day 0 - 1, start of the experiment; Day 21, 3 weeks application of additives

DISCUSSION

Enterococci used as probiotic strains have been found to colonize the digestive tract of various animals, involving food-producing in sufficient amounts up to 10^{3-5} cfu/g (9, 21, 22, 23). *E. faecium* EM41 followed this situation; in our case it ranged from 4.30 to 2.10 log cfu/g. Similarly, Karaffová et al. (24) reported enterocin M-producing and probiotic strain *E. faecium* AL41 in chickens reaching counts up to 10^5 cfu/g to 10^2 cfu/g, also in a group infected with *Campylobacter jejuni* CCM6191. In our study not only *E. faecium* EM41 itself, but also enterocin EM41 (produced by it) showed a tendency to reduce *Campylobacter* cells. Similarly as here with the EM41 strain, Lauková et al. (13) presented the anti-coliform effects of *E. faecium* AL41. The reducing effects of environmental, enterocin A (P) - producing, probiotic strain *E. faecium* EK13=CCM7419 has been demonstrated in the faeces and caecum of gnotobiotic Japanese quails infected with *Salmonella* Duesseldorf SA31 (9). Moreover, Lauková et al. (25) reported stronger therapeutic than prophylactic effects of Ent A (P) against *Salmonella* Duesseldorf SA31 in the digestive tract of gnotobiotic Japanese quails. In addition, Ent A (P) applied before and after the *Salmonella* infection had a protective effect on the duodenal epithelium. The damage to microscopic and submicroscopic structures of enterocytes and goblet cells of the intestinal epithelium and its subsequent necrosis was less intensive after treatment with enterocin A (26). The beneficial effect of poultry-derived strain *Enterococcus faecium* EF55 (probiotic and enterocin-producing) in broilers was also reported by Ševčíková et al. (27). Chickens infected with *Salmonella* Enteritidis and fed a diet supplemented with EF55 strain showed increased proliferative activity of enterocytes in the jejunum. This strain demonstrated positive impact on intestinal morphometry in the jejunum of both non-infected and *Salmonella* infected chickens.

Total protein, albumin and triglycerides were not influenced by the additives. Cholesterol levels have to be controlled regarding the use of hens as food animals. The main sources of cholesterol in human nutrition are animal products. This means, that the idea of reducing concentrations of cholesterol in meat and eggs is very appealing (4). Probiotic bacteria can lower cholesterol by binding cholesterol to the cellular membrane of bacterial cells, through deconjugation of bile salts which may interfere with the enterohepatic cells, or by inhibition of cholesterol synthesis (28, 29). Probiotic

strain *E. faecium* M74 has been found to decrease cholesterol levels in humans (30). Regarding the effect of *E. faecium* EM41 as well as Ent EM41 on cholesterol levels in the blood serum of hens, they were not negatively influenced; they stayed in the range of reference levels. In our experiment, glucose values were higher than the reference values in all groups. However, at day 35 the lowest Glu value was found in EG2 hens (Ent EM41). It is reported that probiotic strain/substance for instance can influence the transport properties of the small intestine epithelium, and increased absorption of glucose could be interpreted as a positive effect on animals (31).

Phagocytosis is an essential component of the cellular innate immunity response and plays an important role in the host defence against infection. In this study, stimulative effect of both additives on PA was found. The beneficial effect of bacteriocin-producing and probiotic strain on PA activity was noted in our previous experiments using a rabbit model (32), but also in laying hens (13). That is, in rabbits after *E. faecium* AL41 application (strain producing Ent M and possessing probiotic properties), PA values reached $48.83\% \pm 0.60$ at the end of the experiment (day 42; in hens it was even higher - $57.0\% \pm 0.66$). However, the highest PA was noted in broiler rabbits at the end of the experiment (day 42) - $68.88\% \pm 0.9$ after Ent M application; so far this is even the highest stimulation of PA influenced by enterocins (33). Karaffová et al. (24) reported modulation of TLR4, TLR21 expression and activation of MIF, IFN- β , MD-2 and CD14 in the caecum of chickens after oral administration of *E. faecium* AL41 to chickens and their infection with *Campylobacter jejuni* CCM6191. It could be stated that continuous preventive application of *E. faecium* AL41 during change of breeding or post hatching, for example, may stimulate the immune system of chickens. Toll-like receptors (TLRs) are pattern recognition receptors that function as microbial infection sensors and are critical for the initiation of the innate inflammatory and adaptive immune response (34). In line with this knowledge, we can suppose that the EM41 strain stimulates PA in this way as well.

GPx belongs among the most abundant antioxidant selenoenzymes protecting cells from oxidative damage (35). Assessing our results, it seems that the additives applied to our hens' diet did not evoke oxidative stress. The results of haematology indicate that additive supplementation did not influence the blood cell profile. They stayed in the range of reference values or were optimized

to the reference value range. Compared to other probiotic enterococci, EM41 did not influence the hens' weight in our study (22).

CONCLUSION

It can be stated in conclusion that *E. faecium* EM 41 isolated from ostrich faeces and its enterocin EM41 showed antimicrobial effects through reduction of CoPS, CoNS, coliforms, *Pseudomonas* spp. and *Aeromonas* spp. PA was stimulated with significant increase after administration of the additive, but they did not negatively influence biochemical, and haematological parameters, or weight gain. Further tests using EM 41 are in process.

CONFLICT OF INTEREST STATEMENT

The authors declared that they have no potential conflict of interest with respect to the authorship and/or publication of this article

ACKNOWLEDGEMENT

These results were obtained in the framework of the projects VEGA 2/0004/14, VEGA 2/0006/17. We would like to thank Mrs. Margita Bodnárová for her excellent laboratory assistance, as well as our colleagues Dr. Miroslav Rýzner and Mrs. Renáta Geročová. Co-author Dr. Renáta Szabóová was employed at our laboratory. Part of the results were involved in the PhD thesis of Dr. Anna Kandričáková (Additive bacteria and their use for health, PhD thesis 2014, University of Veterinary Medicine and Pharmacy, Košice, Slovakia and Institute of Animal Physiology Slovak Academy of Sciences, Košice, Slovakia, pp.1 - 159), and Dr. Jana Ščerbová (Bacteria, bioactive substances and health of animals, PhD thesis 2016, University of Veterinary Medicine and Pharmacy, Košice, Slovakia and Institute of Animal Physiology, Slovak Academy of Sciences, Košice, Slovakia, pp.1 - 159) with my supervision. We would like to thank very much Mr. Andrew Billingham for his kindness to check our English.

REFERENCES

1. Hádryová, J. (2011). Bakteriocín-produkujúce baktérie a ich využitie pre zdravie. Bacteriocin-producing bacteria and their use for health, in Slovak), Diploma thesis, University P. J. Šafárik, Faculty of Natural Science, Institute of Animal Physiology, (p.1- 69).
2. Lauková, A., Hádryová, J., Imrichová, J., Strompfová, J., Kandričáková, A. (2012). Characterization of bacteriocin-producing strain *Enterococcus faecium* EM41, isolate from ostrich and its bacteriocin. Proceedings of Hygiena Alimentorum XXXIII.-Safety and quality of poultry, fish and game products, 9.-11.5. 2011, Štrbské Pleso, Slovakia, pp. 327-4. ISBN 978-80-7148-063-1. PMCid:PMC3419009
3. Kyung-Woo Lee, Duk Kyung Kim, Hyun S. Lillehoj, Seung I. Jang, Sung-Hyen Lee (2015). Immune modulation by *Bacillus subtilis*-based direct-fed microbials in commercial broiler chickens. Anim. Feed Sci. Technol. 200, 76-85.
<https://doi.org/10.1016/j.anifeedsci.2014.12.006>
4. Novak, R., Gogovič Matijašič, M., Terčič, D., Červek, M., Gorjanc, G., Holcman, A., Levart, A., Rogelj, I. (2011). Effects of two probiotic additives containing *Bacillus* spores on carcass characteristics, blood lipids and cecal volatile fatty acids in meat type chickens. Anim. Physiol. Anim. Nutr. 95, 424-433.
<https://doi.org/10.1111/j.1439-0396.2010.01068.x> PMid:21039931
5. Ščerbová, J., Lauková, A. (2016). Sensitivity to enterocins of thermophilic *Campylobacter* sp. from different poultry species. Foodb. Path. Dis. 13, 668-673.
<https://doi.org/10.1089/fpd.2016.2158> PMid:27602434
6. Fuller, R. (2004). What is probiotic. Biologist 51, 232.
7. Murray, A.C., Jr. Hinton, A.Jr., Buhr, R.J. (2006). Effect of botanical probiotic containing lactobacilli on growth performance and population of bacteria in ceca, cloaca and carcass rinse in broiler chicken. Int. J. Polutry Sci. 5, 344-350.
<https://doi.org/10.3923/ijps.2006.344.350>
8. Audisio, M.C., Oliver, G Apella, M.C. (2000). Protective effect of *Enterococcus faecium* J96, a potential probiotic strain, on chicks infected with *Salmonella pullorum*. J. Food Prot. 63, 1333-1337.
<https://doi.org/10.4315/0362-028X-63.10.1333>

9. Lauková, A., Guba, P., Nemcová, R., Vasilková, Z. (2003). Reduction of *Salmonella* in gnotobiotic Japanese quails caused by the enterocin A-producing EK13 strain of *Enterococcus faecium*. *Vet. Res. Com.* 27, 275-280.
<https://doi.org/10.1023/A:1024027923824>
10. Lauková, A., Chrastinová, L., Pogány Simonová, M., Stropfňová, V., Plachá, I., Čobanová, K., Formelová, Z., Chrenková, M., Ondruška, L. (2012). *Enterococcus faecium* AL41: Its Enterocin M and their beneficial use in rabbits husbandry. *Prob. Antimicrob. Prot.* 4, 243-249.
<https://doi.org/10.1007/s12602-012-9118-7>
PMid:26782184
11. Lauková, A., Chrastinová, L., Kandričáková, A., Ščerbová, J., Plachá, I., Pogány Simonová, M., Čobanová, K., Formelová, Z., Ondruška, L., Stropfňová, V. (2015). Bacteriocin substance durancin-like ED26E/7 and its experimental use in broiler rabbits husbandry (in Slovak). *Maso.* 5, 56-59.
12. Levkut, M., Revajová, V., Lauková, A., Ševčíková, Z., Spišáková, V., Faixová, Z., Levkutová, M., Stropfňová, V., Pistl, J., Levkut, M. (2012). Leucocytic responses and intestinal mucin dynamics of broilers protected with *Enterococcus faecium* EF55 and challenged with *Salmonella Enteritidis*. *Res. Vet. Sci.* 93, 195-201.
<https://doi.org/10.1016/j.rvsc.2011.06.021>
PMid:21767856
13. Lauková, A., Stropfňová, V., Plachá, I., Čobanová, K., Faix, Š., Pogány Simonová, M. (2015). Beneficial effect of enterocin M-producing, probiotic strain *Enterococcus faecium* AL41 in model experiment with hens. *Glob. J. Anim. Sci. Res.* 31, 206-213. ISSN:2345-4377.
14. Mareková, M., Lauková, A., De Vuyst, L., Skaugen, M., Nes, I.F. (2003). Partial characterization of bacteriocins produced by environmental strain *Enterococcus faecium* EK13. *J. Appl. Microbiol.* 94, 523-530.
<https://doi.org/10.1046/j.1365-2672.2003.01861.x>
PMid:12588562
15. De Vuyst, L., Callewaert, R., Pot, B. (1996). Characterization of the antagonistic activity of *Lactobacillus amylovorus* DCE471 and large scale isolation of its bacteriocin amylovorin L471. *Syst. Appl. Microbiol.* 19, 9-20.
[https://doi.org/10.1016/S0723-2020\(96\)80003-8](https://doi.org/10.1016/S0723-2020(96)80003-8)
16. Grešáková, L., Boldížárová, K., Čekonová, S., Levkut, M., Leng, L. (2003). Device for quantitative collection of chicken excrement in balance studies. *J. Anim. Feed Sci.* 12, 351-358.
<https://doi.org/10.22358/jafs/67714/2003>
17. Herich, R., Lauková, A., Stropfňová, V., Revajová, V., Levkut, M., Pistl, J. (2004). Optimization of *Salmonella* detection in chickens caecum using PCR method. *Arch. Tierz. Dummerstorf.* 47, 85-91.
18. Woodford N., Egelton C.M., Morrison D. (1997). Comparison of PCR with Phenotypic Methods for the Speciation of Enterococci. In: Horaud T., Bouvet A., Leclercq R., de Montclos H., Sicard M. (eds) *Streptococci and the Host. Advances in Experimental Medicine and Biology*, vol 418. Springer, Boston, MA
https://doi.org/10.1007/978-1-4899-1825-3_97
19. Vetvička, V., Fornousek, J., Kopeček, J., Kaminková, J., Kašpárek, L., Vránová, M. (1982). Phagocytosis of human blood leucocytes, a simple micro method. *Immunol. Lett.* 5, 97-100.
[https://doi.org/10.1016/0165-2478\(82\)90040-2](https://doi.org/10.1016/0165-2478(82)90040-2)
20. Paglia, D.E., Valentine, W.N. (1967). Studies on quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J. Lab. Clin. Med.* 70, 158-169. PMid:6066618
21. Devriese, L.A., Pot, B., Collins, M.D. (1993). Phylogenetic identification of the genus *Enterococcus* and differentiation of phylogenetic distinct of enterococcal species and species groups. *J. Appl. Microbiol.* 75, 399-408.
22. Pogány Simonová, M., Chrastinová, L., Lauková, A., Stropfňová, V., Faix, Š., Vasilková, Z., Ondruška, L., Jurčík, R., Rafay, J. (2009). *Enterococcus faecium* CCM7420, bacteriocin PPB CCM 7420 and their use in the digestive tract of rabbits. *Czech J. Anim. Sci.* 54, 376-386.
23. Stropfňová, V., Lauková, A. (2007). In vitro study on bacteriocin of enterococci associated with chickens. *Anaerobe* 13, 228-237.
<https://doi.org/10.1016/j.anaerobe.2007.07.002>
PMid:17884622
24. Karaffová, V., Marcinková, E., Bobíková, K., Herich, R., Revajová, V., Stašová, D., Kavulová, A., Levkutová, M., Levkut M. Jr., Lauková, A., Ševčíková, Z., Levkut M. Sr. (2017). TLR4 and TLR21 expression, MIF, IFN- β , MID-2, CD14 activation, and IgA production in chickens administered with EFAL41 strain challenged with *Campylobacter jejuni*. *Folia Microbiol.* 62, (2) pp 89-97.
<https://doi.org/10.1007/s12223-016-0475-6>
25. Lauková, A., Guba, P., Nemcová, R., Mareková, M. (2004). Inhibition of *Salmonella enterica* serovar Duesseldorf by enterocin A in gnotobiotic Japanese quails. *Vet. Med. Czech*, 49, 47-51.

26. Cigánková, V., Lauková, A., Guba, P., Nemcová, R. (2004). Effect of enterocin A on the intestinal epithelium of Japanese quails infected by *Salmonella duesseldorf*. Bull. Vet. Inst. 48, 25-27.
27. Ševčíková, Z., Blanár, J., Lauková, A., Revajová, V., Stropfiová, V., Levkut, M. (2016). Effect of *Enterococcus faecium* EF55 on morphometry and proliferative activity of intestinal mucosa in broilers infected with *Salmonella Enteritidis*. J. Vet. Res. 60, 261-265.
<https://doi.org/10.1515/jvetres-2016-0040>
28. De Rodas, B., Z., Gilliland, S.E., Maxwell, C.V. (1996). Hypocholesterolemic action of *Lactobacillus acidophilus* ATCC 43121 and calcium in swine with hypocholesterolemia induced by diet. J. Dairy Sci. 79, 2121-2128.
[https://doi.org/10.3168/jds.S0022-0302\(96\)76586-4](https://doi.org/10.3168/jds.S0022-0302(96)76586-4)
29. Fukushima, M., Nakamo, M. (1995). The effect of probiotic on fecal and liver lipid classes in rats. British J. Nutr. 73, 701-710.
<https://doi.org/10.1079/BJN19950074>
30. Hlivák, P., Odraska, J., Ferenčík, M., Ebringer, L., Jahnová, E., Mikeš, Z. (2005). One-year application of probiotic strain *Enterococcus faecium* M74 decreases serum cholesterol levels. Bratisl. Lek. Listy 106, 67-72.
32. Lauková, A., Pogány Simonová, M., Chrastinová, E., Plachá, I., Čobanová, K., Formelová, Z., Chrenková, M., Ondruška, E., Stropfiová, V. (2016). Benefits of combinative application of probiotic, enterocin M-producing strain *Enterococcus faecium* AL41 and *Eleutherococcus senticosus* in rabbits. Folia Microbiol. 61, 169-177.
<https://doi.org/10.1007/s12223-015-0423-x>
PMid:26354790
33. Pogány Simonová, M., Lauková, A., Plachá, I., Čobanová, K., Stropfiová, V., Szabóová, R., Chrastinová, E. (2013). Can enterocins affect phagocytosis and glutathione-peroxidase in rabbits? Cent. Eur. J. Biol. 8, 730-734.
34. Shang, L., Fukata, M., Thirunarayanan, N., Martin, A.P., Arnaboldi, P., Maussang, D., Berin C, Unleess, J.C., Meyer, L., Abreu, M.T., Lira, S.A. (2008). TLR signaling in small intestinal epithelium promotes B cell recruitment and IgA production in lamina propria. In Gastroenterol. 135, 529-538.
<https://doi.org/10.1053/j.gastro.2008.04.020>
PMid:18522803 PMCID:PMC2598776
35. Mangiapane, E., Pessione, A., Pessione, E. (2014). Selenium and selenoproteins: an overview on different biological systems. Curr. Protein Pept. Sci. 15, 598-607.
<https://doi.org/10.2174/1389203715666140608151134>
PMid:24910086

Please cite this article as: Lauková A., Kandričáková A., Ščerbová J., Szabóová R., Plachá I., Čobanová K., Pogány Simonová M., Stropfiová V. In vivo model experiment using laying hens treated with *Enterococcus faecium* EM41 from ostrich faeces and its enterocin EM41. Mac Vet Rev 2017; 40 (2): 157-166. <https://doi.org/10.1515/macvetrev-2017-0024>